BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 31401845)

  • 1. Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood.
    Hendricks R; Baker D; Brumm J; Davancaze T; Harp C; Herman A; Büdingen HV; Townsend M; Fischer SK
    Bioanalysis; 2019 Aug; 11(15):1405-1418. PubMed ID: 31401845
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
    Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA.
    Koel-Simmelink MJ; Vennegoor A; Killestein J; Blankenstein MA; Norgren N; Korth C; Teunissen CE
    J Immunol Methods; 2014 Jan; 402(1-2):43-9. PubMed ID: 24275679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
    Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T
    Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.
    Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study.
    Gisslén M; Price RW; Andreasson U; Norgren N; Nilsson S; Hagberg L; Fuchs D; Spudich S; Blennow K; Zetterberg H
    EBioMedicine; 2016 Jan; 3():135-140. PubMed ID: 26870824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis.
    Mariotto S; Gajofatto A; Zuliani L; Zoccarato M; Gastaldi M; Franciotta D; Cantalupo G; Piardi F; Polo A; Alberti D; Sartori S; Zanusso G; Agrò L; Demurtas R; Sechi G; Sechi E; Monaco S; Ferrari S
    J Neurol; 2019 Jul; 266(7):1643-1648. PubMed ID: 30944980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
    Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS.
    Thebault S; R Tessier D; Lee H; Bowman M; Bar-Or A; Arnold DL; L Atkins H; Tabard-Cossa V; Freedman MS
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e598. PubMed ID: 31516913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease.
    Andersson E; Janelidze S; Lampinen B; Nilsson M; Leuzy A; Stomrud E; Blennow K; Zetterberg H; Hansson O
    Neurobiol Aging; 2020 Nov; 95():143-153. PubMed ID: 32810755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
    de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A
    Acta Neurol Scand; 2019 May; 139(5):462-468. PubMed ID: 30740668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
    Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
    Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis.
    Le ND; Muri L; Grandgirard D; Kuhle J; Leppert D; Leib SL
    J Neuroinflammation; 2020 Oct; 17(1):293. PubMed ID: 33028339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke.
    Pujol-Calderón F; Portelius E; Zetterberg H; Blennow K; Rosengren LE; Höglund K
    Neurosci Lett; 2019 Apr; 698():58-63. PubMed ID: 30599262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.
    Feneberg E; Oeckl P; Steinacker P; Verde F; Barro C; Van Damme P; Gray E; Grosskreutz J; Jardel C; Kuhle J; Koerner S; Lamari F; Amador MDM; Mayer B; Morelli C; Muckova P; Petri S; Poesen K; Raaphorst J; Salachas F; Silani V; Stubendorff B; Turner MR; Verbeek MM; Weishaupt JH; Weydt P; Ludolph AC; Otto M
    Neurology; 2018 Jan; 90(1):e22-e30. PubMed ID: 29212830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay.
    Ulndreaj A; Sohaei D; Thebault S; Pons-Belda OD; Fernandez-Uriarte A; Campbell C; Cheo D; Stengelin M; Sigal G; Freedman MS; Scarisbrick IA; Prassas I; Diamandis EP
    Diagnosis (Berl); 2023 Aug; 10(3):275-280. PubMed ID: 36788117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
    Halbgebauer S; Steinacker P; Verde F; Weishaupt J; Oeckl P; von Arnim C; Dorst J; Feneberg E; Mayer B; Rosenbohm A; Silani V; Ludolph AC; Otto M
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):68-74. PubMed ID: 34417339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.